fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Showing products 1–24 of 33. More products

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Naproxen EC (02350785), PMS-Naproxen EC (02294702), Naproxen EC (02350793), PMS-Naproxen EC (02294710), Naproxen EC (02350807), PMS-Naproxen (02017237), Naprosyn (02162458), Naproxen (02350750), Naproxen (02350769), Naproxen (02350777), Naproxen Sodium (02351013), Naproxen Sodium DS (02351021). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Naproxen

Form:

21 of 21 products shown

8 general benefit · 13 not a benefit

Pediapharm Naproxen Suspension · DIN 02162431 · 25 mg/mL · oral liquid

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
Pediapharm Naproxen Suspension · DIN 02162431 Manufacturer: Medexus Pharmaceuticals Inc.; listing date 1996-10-01 Health Canada: Marketed since 2022-12-20 · brand PEDIAPHARM NAPROXEN SUSPENSION · ATC M01AE02 NAPROXEN · form Suspension · route Oral · ingredients NAPROXEN 25 MG/ML · company Medexus pharmaceuticals inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Pediapharm Naproxen Suspension: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0949). What the ministry pays, not the patient.

Ministry pays: $0.0949 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02162431)

Source record
DIN 02162431: Pediapharm Naproxen Suspension Raw flags: sec3=Y Item: 280804054; group id 389; item number 0931; lccId None; manufacturer id MPI Source form: O/L; strength: 25mg/mL Recorded listing: General benefit Source prices (unrounded): $0.0949; ministry $0.0949 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02162431 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19661 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02162431
Shortage record checked October 6, 2026

Apo-Naproxen · DIN 00522651 · 250 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Naproxen · DIN 00522651 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1982-12-31 · brand APO-NAPROXEN · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 250 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Naproxen: Formulary list price $0.11 per unit (the source does not state the unit; exact figure $0.1068). What the ministry pays, not the patient.

Ministry pays: $0.1068 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00522651)

Source record
DIN 00522651: Apo-Naproxen Raw flags: sec3=Y Item: 280804034; group id 389; item number 0933; lccId None; manufacturer id APX Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.1068; ministry $0.1068 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00522651 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4980 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Naprosyn · DIN 02162474 · not recorded Teva-Naproxen · DIN 00565350 · $0.1068
Shortage status: resolved shortage (ended August 20, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00522651
Shortage record checked October 6, 2026

Teva-Naproxen · DIN 00565350 · 250 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Naproxen · DIN 00565350 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2010-08-04 · brand TEVA-NAPROXEN · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 250 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Naproxen: Formulary list price $0.11 per unit (the source does not state the unit; exact figure $0.1068). What the ministry pays, not the patient.

Ministry pays: $0.1068 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00565350)

Source record
DIN 00565350: Teva-Naproxen Raw flags: sec3=Y Item: 280804034; group id 389; item number 0933; lccId None; manufacturer id TEV Source form: Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.1068; ministry $0.1068 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00565350 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5036 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Naproxen · DIN 00522651 · $0.1068 Naprosyn · DIN 02162474 · not recorded
Shortage status: shortage reported ended July 31, 2026 (report last updated July 31, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00565350
Shortage record checked October 6, 2026

Apo-Naproxen · DIN 00600806 · 375 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Naproxen · DIN 00600806 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1983-12-31 · brand APO-NAPROXEN · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 375 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Naproxen: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1458). What the ministry pays, not the patient.

Ministry pays: $0.1458 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00600806)

Source record
DIN 00600806: Apo-Naproxen Raw flags: sec3=Y Item: 280804035; group id 389; item number 0934; lccId None; manufacturer id APX Source form: Tab; strength: 375mg Recorded listing: General benefit Source prices (unrounded): $0.1458; ministry $0.1458 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00600806 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5508 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Naprosyn · DIN 02162482 · not recorded Teva-Naproxen · DIN 00627097 · $0.1458
Shortage status: active shortage (reported September 29, 2026, estimated to end October 30, 2026, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00600806
Shortage record checked October 6, 2026

Teva-Naproxen · DIN 00627097 · 375 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Naproxen · DIN 00627097 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2010-08-04 · brand TEVA-NAPROXEN · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 375 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Naproxen: Formulary list price $0.15 per unit (the source does not state the unit; exact figure $0.1458). What the ministry pays, not the patient.

Ministry pays: $0.1458 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00627097)

Source record
DIN 00627097: Teva-Naproxen Raw flags: sec3=Y Item: 280804035; group id 389; item number 0934; lccId None; manufacturer id TEV Source form: Tab; strength: 375mg Recorded listing: General benefit Source prices (unrounded): $0.1458; ministry $0.1458 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00627097 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5860 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Naproxen · DIN 00600806 · $0.1458 Naprosyn · DIN 02162482 · not recorded
Shortage status: resolved shortage (ended June 24, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00627097
Shortage record checked October 6, 2026

Apo-Naproxen · DIN 00592277 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Naproxen · DIN 00592277 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1983-12-31 · brand APO-NAPROXEN · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 500 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Naproxen: Formulary list price $0.45 per unit (the source does not state the unit; exact figure $0.4522). What the ministry pays, not the patient.

Ministry pays: $0.4522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00592277)

Source record
DIN 00592277: Apo-Naproxen Raw flags: sec3=Y Item: 280804036; group id 389; item number 0935; lccId None; manufacturer id APX Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.4522; ministry $0.4522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00592277 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5222 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Naprosyn · DIN 02162490 · not recorded Teva-Naproxen · DIN 00589861 · $0.4522
Shortage status: resolved shortage (ended August 20, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00592277
Shortage record checked October 6, 2026

Teva-Naproxen · DIN 00589861 · 500 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Naproxen · DIN 00589861 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2010-08-04 · brand TEVA-NAPROXEN · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 500 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Naproxen: Formulary list price $0.45 per unit (the source does not state the unit; exact figure $0.4522). What the ministry pays, not the patient.

Ministry pays: $0.4522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00589861)

Source record
DIN 00589861: Teva-Naproxen Raw flags: sec3=Y Item: 280804036; group id 389; item number 0935; lccId None; manufacturer id TEV Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.4522; ministry $0.4522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00589861 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5183 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Naproxen · DIN 00592277 · $0.4522 Naprosyn · DIN 02162490 · not recorded
Shortage status: resolved shortage (ended January 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00589861
Shortage record checked October 6, 2026

Apo-Naproxen EC · DIN 02246699 · 250 mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Naproxen EC · DIN 02246699 Manufacturer: Apotex Inc.; listing date 2008-01-15 Health Canada: Marketed since 2003-04-23 · brand APO-NAPROXEN EC TABLETS · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 250 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02246699)

Source record
DIN 02246699: Apo-Naproxen EC Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804100; group id 389; item number 0928; lccId None; manufacturer id APX Source form: Ent Tab; strength: 250mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.2835; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02246699 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70894 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Naprosyn E · DIN 02162792 · not recorded Teva-Naproxen EC · DIN 02243312 · not recorded
Shortage status: resolved shortage (ended September 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246699
Shortage record checked October 6, 2026

Teva-Naproxen EC · DIN 02243312 · 250 mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Naproxen EC · DIN 02243312 Manufacturer: Teva Canada Limited; listing date 2008-11-04 Health Canada: Marketed since 2010-08-04 · brand TEVA-NAPROXEN EC · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 250 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02243312)

Source record
DIN 02243312: Teva-Naproxen EC Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804100; group id 389; item number 0928; lccId None; manufacturer id TEV Source form: Ent Tab; strength: 250mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.2835; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243312 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67215 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Naproxen EC · DIN 02246699 · not recorded Naprosyn E · DIN 02162792 · not recorded
Shortage status: resolved shortage (ended January 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243312
Shortage record checked October 6, 2026

Apo-Naproxen EC · DIN 02246700 · 375 mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Naproxen EC · DIN 02246700 Manufacturer: Apotex Inc.; listing date 2008-01-15 Health Canada: Marketed since 2003-04-23 · brand APO-NAPROXEN EC · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 375 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02246700)

Source record
DIN 02246700: Apo-Naproxen EC Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804101; group id 389; item number 0929; lccId None; manufacturer id APX Source form: Ent Tab; strength: 375mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3675; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02246700 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70895 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Naprosyn E · DIN 02162415 · not recorded Teva-Naproxen EC · DIN 02243313 · not recorded
Shortage status: resolved shortage (ended October 19, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246700
Shortage record checked October 6, 2026

Teva-Naproxen EC · DIN 02243313 · 375 mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Naproxen EC · DIN 02243313 Manufacturer: Teva Canada Limited; listing date 2008-11-04 Health Canada: Marketed since 2010-08-04 · brand TEVA-NAPROXEN EC · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 375 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02243313)

Source record
DIN 02243313: Teva-Naproxen EC Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804101; group id 389; item number 0929; lccId None; manufacturer id TEV Source form: Ent Tab; strength: 375mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3675; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243313 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67216 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Naproxen EC · DIN 02246700 · not recorded Naprosyn E · DIN 02162415 · not recorded
Shortage status: resolved shortage (ended February 4, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243313
Shortage record checked October 6, 2026

Apo-Naproxen EC · DIN 02246701 · 500 mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Naproxen EC · DIN 02246701 Manufacturer: Apotex Inc.; listing date 2008-01-15 Health Canada: Marketed since 2003-04-23 · brand APO-NAPROXEN EC · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 500 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02246701)

Source record
DIN 02246701: Apo-Naproxen EC Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804102; group id 389; item number 0930; lccId None; manufacturer id APX Source form: Ent Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6894; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02246701 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70896 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Naprosyn E · DIN 02162423 · not recorded Teva-Naproxen EC · DIN 02243314 · not recorded
Shortage status: resolved shortage (ended September 24, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246701
Shortage record checked October 6, 2026

Naprosyn E · DIN 02162423 · 500 mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Naprosyn E · DIN 02162423 Manufacturer: Hoffmann-La Roche Limited; listing date 2008-01-15 Health Canada: Marketed since 2025-04-24 · brand NAPROSYN · ATC M01AE02 NAPROXEN · form Tablet (delayed-release) · route Oral · ingredients NAPROXEN 500 MG · company Searchlight pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Naprosyn E: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02162423)

Source record
DIN 02162423: Naprosyn E Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804102; group id 389; item number 0930; lccId None; manufacturer id HLR Source form: Ent Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02162423 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19315 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Naproxen EC · DIN 02246701 · not recorded Teva-Naproxen EC · DIN 02243314 · not recorded
Shortage status: active shortage (reported January 30, 2023, last updated July 27, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02162423
Shortage record checked October 6, 2026

Teva-Naproxen EC · DIN 02243314 · 500 mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Naproxen EC · DIN 02243314 Manufacturer: Teva Canada Limited; listing date 2008-11-04 Health Canada: Marketed since 2010-08-04 · brand TEVA-NAPROXEN EC · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 500 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02243314)

Source record
DIN 02243314: Teva-Naproxen EC Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804102; group id 389; item number 0930; lccId None; manufacturer id TEV Source form: Ent Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.6894; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243314 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67217 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Naproxen EC · DIN 02246701 · not recorded Naprosyn E · DIN 02162423 · not recorded
Shortage status: resolved shortage (ended December 10, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243314
Shortage record checked October 6, 2026

Apo-Naproxen · DIN 00522678 · 125 mg · tablet

General benefitDormant since August 8, 2019 · checked October 5, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Apo-Naproxen · DIN 00522678 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Dormant since 2019-08-08 · brand APO NAPROXEN TAB 125MG · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 125 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Naproxen: Formulary list price $0.08 per unit (the source does not state the unit; exact figure $0.0781). What the ministry pays, not the patient.

Ministry pays: $0.0781 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00522678)

Source record
DIN 00522678: Apo-Naproxen Raw flags: sec3=Y Item: 280804033; group id 389; item number 0932; lccId None; manufacturer id APX Source form: Tab; strength: 125mg Recorded listing: General benefit Source prices (unrounded): $0.0781; ministry $0.0781 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00522678 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4981 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Naprosyn · DIN 00299413 · not recorded
Shortage status: discontinued (August 5, 2019, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00522678
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 8, 2019 — choose a marketed DIN from the same-category list.

Naprosyn · PIN 00299413 · 125 mg · tablet

Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
1 brand, same coverage
Naprosyn · DIN 00299413 Manufacturer: Syntex Inc.; listing date 2001-02-28 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Naprosyn: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 00299413)

Source record
DIN 00299413: Naprosyn Raw flags: notABenefit=Y, sec3=Y Item: 280804033; group id 389; item number 0932; lccId None; manufacturer id SYN Source form: Tab; strength: 125mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00299413 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Naproxen · DIN 00522678 · $0.0781
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00299413
Shortage record checked October 6, 2026

Naprosyn E · DIN 02162792 · 250 mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2014-02-05 — choose a marketed DIN from the same-category list.Discontinued February 5, 2014 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2014-02-05 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2014-02-05 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Naprosyn E · DIN 02162792 Manufacturer: Hoffmann-La Roche Limited; listing date 2008-01-15 Health Canada: Cancelled post market since 2014-02-05 · brand NAPROSYN E 250MG TABLETS - ECT · ATC M01AE02 NAPROXEN · form Tablet (enteric-coated) · route Oral · ingredients NAPROXEN 250 MG · company Hoffmann-la roche limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Naprosyn E: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02162792)

Source record
DIN 02162792: Naprosyn E Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804100; group id 389; item number 0928; lccId None; manufacturer id HLR Source form: Ent Tab; strength: 250mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02162792 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19448 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Naproxen EC · DIN 02246699 · not recorded Teva-Naproxen EC · DIN 02243312 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02162792
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 5, 2014 — choose a marketed DIN from the same-category list.

Naprosyn · DIN 02162474 · 250 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-01-22 — choose a marketed DIN from the same-category list.Discontinued January 22, 2002 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-01-22 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-01-22 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Naprosyn · DIN 02162474 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2002-01-22 · brand NAPROSYN 250MG TABLETS · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 250 MG/TAB · company Hoffmann-la roche limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Naprosyn: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02162474)

Source record
DIN 02162474: Naprosyn Raw flags: notABenefit=Y, sec3=Y Item: 280804034; group id 389; item number 0933; lccId None; manufacturer id HLR Source form: Tab; strength: 250mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02162474 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19445 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Naproxen · DIN 00522651 · $0.1068 Teva-Naproxen · DIN 00565350 · $0.1068
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02162474
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 22, 2002 — choose a marketed DIN from the same-category list.

Naprosyn E · DIN 02162415 · 375 mg · enteric-coated tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-25 — choose a marketed DIN from the same-category list.Discontinued July 25, 2025 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-25 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2025-07-25 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Naprosyn E · DIN 02162415 Manufacturer: Hoffmann-La Roche Limited; listing date 2008-01-15 Health Canada: Cancelled post market since 2025-07-25 · brand NAPROSYN · ATC M01AE02 NAPROXEN · form Tablet (delayed-release) · route Oral · ingredients NAPROXEN 375 MG · company Searchlight pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Naprosyn E: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02162415)

Source record
DIN 02162415: Naprosyn E Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804101; group id 389; item number 0929; lccId None; manufacturer id HLR Source form: Ent Tab; strength: 375mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02162415 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19316 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Naproxen EC · DIN 02246700 · not recorded Teva-Naproxen EC · DIN 02243313 · not recorded
Shortage status: discontinued (July 31, 2024, reported by ATNAHS PHARMA UK LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02162415
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 25, 2025 — choose a marketed DIN from the same-category list.

Naprosyn · DIN 02162482 · 375 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-06-27 — choose a marketed DIN from the same-category list.Discontinued June 27, 2001 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2001-06-27 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2001-06-27 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Naprosyn · DIN 02162482 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2001-06-27 · brand NAPROSYN 375MG TABLETS · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 375 MG · company Hoffmann-la roche limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Naprosyn: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02162482)

Source record
DIN 02162482: Naprosyn Raw flags: notABenefit=Y, sec3=Y Item: 280804035; group id 389; item number 0934; lccId None; manufacturer id HLR Source form: Tab; strength: 375mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02162482 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19660 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Naproxen · DIN 00600806 · $0.1458 Teva-Naproxen · DIN 00627097 · $0.1458
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02162482
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 27, 2001 — choose a marketed DIN from the same-category list.

Naprosyn · DIN 02162490 · 500 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-09 — choose a marketed DIN from the same-category list.Discontinued July 9, 2002 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-07-09 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-07-09 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Naprosyn · DIN 02162490 Manufacturer: Hoffmann-La Roche Limited; listing date 2000-04-17 Health Canada: Cancelled post market since 2002-07-09 · brand NAPROSYN 500 MG TABLETS · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN 500 MG · company Hoffmann-la roche limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Naprosyn: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02162490)

Source record
DIN 02162490: Naprosyn Raw flags: notABenefit=Y, sec3=Y Item: 280804036; group id 389; item number 0935; lccId None; manufacturer id HLR Source form: Tab; strength: 500mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02162490 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19696 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Naproxen · DIN 00592277 · $0.4522 Teva-Naproxen · DIN 00589861 · $0.4522
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02162490
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 9, 2002 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (M01A, M01AE): coverage varies; not interchangeable

  • Flurbiprofen (Ansaid): general benefit, not a benefit
  • Ibuprofen (Motrin): general benefit, not a benefit
  • Ketoprofen: general benefit, not a benefit
  • Tiaprofenic acid (Surgam): general benefit, not a benefit
  • Oxaprozin (Daypro): not a benefit
  • Diclofenac (Voltaren): general benefit, not a benefit

10 more in the class list below

Naproxen sodium

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules
StatusOff-Formulary Interchangeable, not an ODB benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

Anaprox · DIN 02162725 · 275 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Anaprox · DIN 02162725 Manufacturer: Hoffmann-La Roche Limited; listing date 2007-12-19 Health Canada: Marketed since 2025-06-26 · brand ANAPROX · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN SODIUM 275 MG · company Searchlight pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Anaprox: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02162725)

Source record
DIN 02162725: Anaprox Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804103; group id 391; item number 0938; lccId None; manufacturer id HLR Source form: Tab; strength: 275mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02162725 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19446 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Napro-Na · DIN 00784354 · not recorded Teva-Naproxen Sodium · DIN 00778389 · not recorded
Shortage status: active shortage (reported July 25, 2024, last updated July 27, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02162725
Shortage record checked October 6, 2026

Apo-Napro-Na · DIN 00784354 · 275 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Apo-Napro-Na · DIN 00784354 Manufacturer: Apotex Inc.; listing date 2007-12-19 Health Canada: Marketed since 1989-12-31 · brand APO-NAPRO-NA · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN SODIUM 275 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00784354)

Source record
DIN 00784354: Apo-Napro-Na Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804103; group id 391; item number 0938; lccId None; manufacturer id APX Source form: Tab; strength: 275mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3422; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00784354 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10035 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Anaprox · DIN 02162725 · not recorded Teva-Naproxen Sodium · DIN 00778389 · not recorded
Shortage status: resolved shortage (ended August 19, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00784354
Shortage record checked October 6, 2026

Teva-Naproxen Sodium · DIN 00778389 · 275 mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives
1 brand, same coverage
Teva-Naproxen Sodium · DIN 00778389 Manufacturer: Teva Canada Limited; listing date 2022-08-31 Health Canada: Marketed since 2010-07-20 · brand TEVA-NAPROXEN SODIUM · ATC M01AE02 NAPROXEN · form Tablet · route Oral · ingredients NAPROXEN SODIUM 275 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00778389)

Source record
DIN 00778389: Teva-Naproxen Sodium Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 280804103; group id 391; item number 0938; lccId None; manufacturer id TEV Source form: Tab; strength: 275mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.3422; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00778389 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9241 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Anaprox · DIN 02162725 · not recorded Apo-Napro-Na · DIN 00784354 · not recorded
Shortage status: resolved shortage (ended February 18, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00778389
Shortage record checked October 6, 2026

Other products in the same Health Canada class (M01A, M01AE): coverage varies; not interchangeable

  • Flurbiprofen (Ansaid): general benefit, not a benefit
  • Ibuprofen (Motrin): general benefit, not a benefit
  • Ketoprofen: general benefit, not a benefit
  • Tiaprofenic acid (Surgam): general benefit, not a benefit
  • Oxaprozin (Daypro): not a benefit
  • Diclofenac (Voltaren): general benefit, not a benefit

10 more in the class list below

Other drugs in the same formulary class (28:08:04 Nonsteroidal Anti-Inflammatory Agents) and how they are covered

Matched class: 28:08:04 Nonsteroidal Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DICLOFENAC SODIUM & MISOPROSTOL Some products covered without a code (check the product listing): DICLOFENAC SODIUM, FLURBIPROFEN, IBUPROFEN, INDOMETHACIN, KETOPROFEN, MEFENAMIC ACID, MELOXICAM, PIROXICAM, SULINDAC, TIAPROFENIC ACID 28:08:04 Nonsteroidal Anti-Inflammatory Agents

FLURBIPROFEN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50mg, 100mg · Tab

IBUPROFEN

· 11 products · Listed, not a benefit (3), General benefit (7), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 200mg, 300mg, 400mg, 600mg · Tab

KETOPROFEN

· 9 products · General benefit (4), Listed, not a benefit (5) · strengths: 50mg, 100mg, 200mg · Cap, Ent Tab, LA Tab

TIAPROFENIC ACID

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 200mg, 300mg · Tab

OXAPROZIN.

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 600mg · Tab

DICLOFENAC SODIUM

· 19 products · Listed, not a benefit (3), General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 25mg, 50mg, 75mg, 100mg, 1.5% W/W · Ent Tab, LA Tab, Sup, Top Sol

DICLOFENAC SODIUM & MISOPROSTOL

· 6 products · General benefit · strengths: 50mg & 200mcg, 75mg & 200mcg · Tab

INDOMETHACIN

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 25mg, 50mg, 100mg · Cap, Sup

MEFENAMIC ACID

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

MELOXICAM

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 7.5mg, 15mg · Tab

PIROXICAM

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 10mg, 20mg · Cap

SULINDAC

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 150mg, 200mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:08:04 and 4 more
Full class listing Related classes: 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS APO-NAPROXEN (naproxen) is indicated for: • The treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. • The relief of minor aches and pains in muscles, bones and joints, mild to moderate pain accompanied by inflammation in musculoskeletal injuries (sprains and strains) and primary dysmenorrhea. Modified release formulations of naproxen (i.e., enteric coated and sustained release) are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed. For patients with an increased risk of developing cardiovascular and/or gastrointestinal adverse events, other management strategies that do NOT include the use of NSAIDs should be considered first. See 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS. Use of APO-NAPROXEN should be limited to the lowest effective dose for the shortest possible duration of treatment in order to minimize the potential risk for cardiovascular or gastrointestinal adverse events. See 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS APO-NAPROXEN, as a NSAID, does NOT treat clinical disease or prevent its progression. APO-N… https://pdf.hres.ca/dpd_pm/00071788.PDF PM date: July 26, 2023 Source product: APO-NAPROXEN; DIN 00522651; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS TEVA-NAPROXEN SODIUM or TEVA-NAPROXEN SODIUM DS (naproxen sodium) is indicated for:  The relief of mild to moderately severe pain, accompanied by inflammation in conditions such as musculoskeletal trauma and post-dental extraction.  The relief of pain associated with post-partum cramping and dysmenorrhea. For patients with an increased risk of developing cardiovascular and/or gastrointestinal adverse events, other management strategies that do NOT include the use of NSAIDs should be considered first. (See 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS) Use of TEVA-NAPROXEN SODIUM or TEVA-NAPROXEN SODIUM DS should be limited to the lowest effective dose for the shortest possible duration of treatment in order to minimize the potential risk for cardiovascular or gastrointestinal adverse events. (See 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS) TEVA-NAPROXEN SODIUM or TEVA-NAPROXEN SODIUM DS, as a NSAID, does NOT treat clinical disease or prevent its progression. TEVA-NAPROXEN SODIUM and TEVA-NAPROXEN SODIUM DS, as a NSAID, only relieves symptoms and decreases inflammation for as long as the patient continues to take it. 1.1 … https://pdf.hres.ca/dpd_pm/00066719.PDF PM date: July 18, 2022 Source product: TEVA-NAPROXEN SODIUM; DIN 00778389; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS VIMOVO (naproxen/esomeprazole) is indicated for the treatment of the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) and to decrease the risk of developing gastric ulcers in patients at risk for developing non-steroidal anti- inflammatory drug (NSAID)-associated gastric ulcers. VIMOVO is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed (as with other modified release formulations of naproxen). For patients with an increased risk of developing cardiovascular (CV) and/or gastrointestinal (GI) adverse events, other management strategies that do NOT include the use of NSAIDs should be considered first (see 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS). Use of VIMOVO should be limited to the lowest effective dose for the shortest possible duration of treatment in order to minimize the potential risk for cardiovascular or gastrointestinal ad verse events (see 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS). VIMOVO, as a NSAID, does NOT treat clinical disease or prevent its progression. VIMOVO, as a NSAID, only relieves symptoms and decreases inflammation for … https://pdf.hres.ca/dpd_pm/00068301.PDF PM date: Nov 16, 2022 Source product: VIMOVO; DIN 02361701; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Naproxen · DIN 00565350 Shortage status: shortage reported ended 2026-07-31 (report last updated 2026-07-31); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00565350

Check this DIN again

Apo-Naproxen · DIN 00600806 Shortage status: active shortage (reported 2026-09-29, estimated to end 2026-10-30, last updated 2026-10-02); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00600806

Check this DIN again

Naprosyn E · DIN 02162423 Shortage status: active shortage (reported 2023-01-30, last updated 2026-07-27); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02162423

Check this DIN again

Apo-Naproxen · DIN 00522678 Shortage status: discontinued (2019-08-05, reported by APOTEX INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00522678

Check this DIN again

Naprosyn E · DIN 02162415 Shortage status: discontinued (2024-07-31, reported by ATNAHS PHARMA UK LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02162415

Check this DIN again

Anaprox · DIN 02162725 Shortage status: active shortage (reported 2024-07-25, last updated 2026-07-27); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02162725

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Apo-Naproxen EC, Teva-Naproxen EC, Naprosyn E, Naprosyn, Anaprox, Apo-Napro-Na, Teva-Naproxen Sodium: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026